Multicenter prospective cohort study to identify high-risk group for primary gastric cancer using DNA methylation levels in normal-appearing gastric tissues in healthy people after Helicobacter pylori eradication - Risk prediction of gastric cancer after H. pylori eradication

Hoshi University0 个研究点目标入组 1,880 人开始时间: 2015年3月24日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•1) Synchronous or metachronous (within 5 years) malignancies, except for carcinoma in situ or mucosal tumors curatively treated with local therapy. 2) Past history of gastrectomy, endoscopic treatment of a gastric tumor, and reconstructive surgery with a stomach tube for an esophageal cancer. 3) Past history of receiving chemotherapy (including endocrinotherapy) or radiation therapy against any other malignancies. 4) Suspicious gastric tumor by endoscopy or gastric biopsy at the time of eradication. 5) Psychosis. 6) Systemic steroid medication. 7) Individuals with two or more kinds of antiplatelet medications, with anticoagulant medication, or with coagulopathy. 8) Active gastrointestinal bleeding. 9) Individuals considered unsuitable for biopsy by an endoscopist. 10) Individuals with hereditary gastrointestinal tumors, including familial adenomatous polyposis (FAP), Lynch syndrome or Hereditary non-polyposis colorectal cancer (HNPCC), Peutz-Jeghers syndrome, Cowden syndrome, and Hereditary diffuse gastric cancer.

发起方